FDA (CDER)
GUIDANCE DRAFT
Q3E Guideline for Extractables and Leachables
Published: 11/28/2025Detected: 3/20/2026
Summary preview
Provides draft FDA (CDER) guidance on extractables and leachables (E/L), which may shape expectations for safety and risk-based assessment of materials in drug manufacturing and packaging systems.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
safety
labeling
#extractables
#leachables
#packaging
#patient exposure
#risk assessment
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry9/8/2026
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
- Evaluation of Therapeutic Equivalence8/21/2026
- Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026